These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9878023)

  • 41. Animal model of human disease. Bacillary dysentery, shigellosis, Shigella dysentery. Animal model: Monkey shigellosis or dysentery.
    Takeuchi A; Jervis HR; Formal SB
    Am J Pathol; 1975 Oct; 81(1):251-4. PubMed ID: 810032
    [No Abstract]   [Full Text] [Related]  

  • 42. Feeding potato flakes affects cecal short-chain fatty acids, microflora and fecal bile acids in rats.
    Han KH; Hayashi N; Hashimoto N; Shimada K; Sekikawa M; Noda T; Fukushima M
    Ann Nutr Metab; 2008; 52(1):1-7. PubMed ID: 18235187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of M cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis.
    Wassef JS; Keren DF; Mailloux JL
    Infect Immun; 1989 Mar; 57(3):858-63. PubMed ID: 2645214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders.
    Gill PA; van Zelm MC; Muir JG; Gibson PR
    Aliment Pharmacol Ther; 2018 Jul; 48(1):15-34. PubMed ID: 29722430
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lactoferrin protects rabbits from Shigella flexneri-induced inflammatory enteritis.
    Gomez HF; Ochoa TJ; Herrera-Insua I; Carlin LG; Cleary TG
    Infect Immun; 2002 Dec; 70(12):7050-3. PubMed ID: 12438385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis.
    Taylor DN; McKenzie R; Durbin A; Carpenter C; Haake R; Bourgeois AL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1179-81. PubMed ID: 18086855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of reactivation of shigellosis in naturally infected enrofloxacin-treated cynomolgus monkeys after exogenous immunosuppression.
    Black-Schultz L; Coatney RW; Warnick CL; Swif B
    Lab Anim Sci; 1997 Dec; 47(6):602-5. PubMed ID: 9433696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study.
    Guillemot F; Colombel JF; Neut C; Verplanck N; Lecomte M; Romond C; Paris JC; Cortot A
    Dis Colon Rectum; 1991 Oct; 34(10):861-4. PubMed ID: 1914718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-chain fatty acids in ulcerative colitis.
    Kim YI
    Nutr Rev; 1998 Jan; 56(1 Pt 1):17-24. PubMed ID: 9481114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Shigellosis murine model established by intraperitoneal and intranasal route of administration: a comparative comprehension overview.
    Sharma D; Yagnik B; Baksi R; Desai N; Padh H; Desai P
    Microbes Infect; 2017 Jan; 19(1):47-54. PubMed ID: 27664045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial.
    Raqib R; Sarker P; Mily A; Alam NH; Arifuzzaman AS; Rekha RS; Andersson J; Gudmundsson GH; Cravioto A; Agerberth B
    BMC Infect Dis; 2012 May; 12():111. PubMed ID: 22574737
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical and morphological aspects of shigellosis flexneri in patients with an aggravated premorbid state].
    Iushchuk ND; Rozenblium AIu; Parkhomenko IuG; Efremova LV; Tishkevich OA; Karmanov MI; Kanshina NN; Burov VP; Bergman GA
    Zh Mikrobiol Epidemiol Immunobiol; 2002; (2):77-9. PubMed ID: 12043161
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Local short-chain fatty acids supplementation without beneficial effect on inflammation in excluded rectum.
    Schauber J; Bark T; Jaramillo E; Katouli M; Sandstedt B; Svenberg T
    Scand J Gastroenterol; 2000 Feb; 35(2):184-9. PubMed ID: 10720118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical manifestations and treatment of intestinal dysbacteriosis in patients with Flexner's dysentery].
    Shakhmardanov MZ; Luchshev VI; Bondarenko VM; Isaeva NN
    Klin Med (Mosk); 1997; 75(7):47-9. PubMed ID: 9411056
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Treatment of severe dysentery].
    Shakhmardanov MZ; Luchshev VI; Isaeva NP; Bondarenko VM
    Klin Med (Mosk); 1997; 75(11):69-71. PubMed ID: 9490365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Experimental shigellosis and intestinal malabsorption in the mouse.
    Madge DS
    Comp Biochem Physiol A Comp Physiol; 1974 Jun; 48(2):343-59. PubMed ID: 4151366
    [No Abstract]   [Full Text] [Related]  

  • 57. Experimental model of dysentery.
    Galikeyev KL; Shevchenko TF
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(1):37-43. PubMed ID: 6806355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy.
    Sarker P; Ahmed S; Tiash S; Rekha RS; Stromberg R; Andersson J; Bergman P; Gudmundsson GH; Agerberth B; Raqib R
    PLoS One; 2011; 6(6):e20637. PubMed ID: 21673991
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Shigellosis--an overview.
    Bhattacharya MK; Chakraborty MK; Dutta D; Dutta P; Bhattacharya SK
    J Indian Med Assoc; 1993 Mar; 91(3):72-4. PubMed ID: 8350007
    [No Abstract]   [Full Text] [Related]  

  • 60. Endemic enteric disease in vervet monkeys.
    Fincham JE; Seier JV
    J S Afr Vet Assoc; 1981 Sep; 52(3):177-9. PubMed ID: 7031245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.